SOURCE: Crucell N.V.

December 08, 2006 02:06 ET

Crucell Awarded an additional Quinvaxem™ Vaccine contract of over $20 Million for 2007

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- December 8, 2006 --



PRESS RELEASE

                    Crucell Awarded an additional
     Quinvaxem™ Vaccine contract of over $20 Million for 2007
Leiden, The Netherlands, December 8, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has been awarded an additional contract totaling over US$ 20 million for its Quinvaxem™ pediatric vaccine. This contract was awarded by a supranational organization for Latin America and covers sales in 2007.

This contract is valid for 2007 and in addition to the contract which has been awarded to Crucell December 1 by supranational organizations totaling over US$ 230 million for both its Quinvaxem™ and Hepavax-Gene® pediatric vaccines representing minimum sales to these supranational organizations over the next three years including 2009.

Following the WHO pre-qualification in September 2006, the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.

Quinvaxem™, a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell's laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis and pneumonia in children.

Current worldwide demand for the Quinvaxem™ vaccine exceeds 50 million doses per year. The total market potential is 150 million doses per year in 3 to 4 years time.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

For further information please contact:


Crucell N.V.
Leonard Kruimer
Chief Financial Officer
Tel. +31 (0)71 524 8722
l.kruimer@crucell.com

For Crucell in the US:
Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733
tredington@redingtoninc.com




Copyright © Hugin ASA 2006. All rights reserved.

Contact Information